

N 09/703,350

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	MEHRABAN ET AL.	Examiner:	G. NICKOL
Serial No.:	09/703,350	Group Art Unit:	1642
Filed:	OCTOBER 31, 2000	Docket No.:	11669.213USU1
Confirmation No.:	3065	Customer No.:	23552
Title:	DIFFERENTIALLY EXPRESSED GENES INVOLVED IN ANGIOGENESIS, THE POLYPEPTIDES ENCODED THEREBY, AND METHODS OF USING THE SAME		

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 639593368 US
Date of Deposit: February 1, 2006

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop RCE, Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450.

By:

Name: Sheryl A. Boerboom

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing of a first Office Action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d). Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. § 1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.


Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: February 1, 2006

Katherine M. Kowalchyk
Katherine M. Kowalchyk
Reg. No. 36,848




FORM 1449* 	INFORMATION DISCLOSURE STATEMENT		Docket Number: 11669.213USU1	Application Number: 09/703,350
	IN AN APPLICATION		Applicant: MEHRABAN ET AL.	
	(Use several sheets if necessary)		Filing Date: 10/31/2000	Group Art Unit: 1642

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,547,856	08/20/1996	Godowski et al.			
	6,099,841	08/08/2000	Hillanetal.			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 01/30969	05/03/2001	PCT				
	WO 01/32926	05/10/2001	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Bussolino et al., "Hepatocyte Growth Factor is a Potent Angiogenic Factor Which Stimulates Endothelial Cell Motility and Growth", <u>Journal of Cell Biology</u> , 119(3):629-641 (1992)
		Couffinhal et al., "Animal Model: Mouse Model of Angiogenesis", <u>American Journal of Pathology</u> , 152(6):1667-1679 (1998)
		Ferrara, N., "Role of Vascular Endothelial Growth Factor in Physiologic and Pathologic Angiogenesis: Therapeutic Implications", <u>Seminars in Oncology</u> , 29(6):Suppl.16:10-14 (2002)
		Filvaroff et al., "Stanniocalcin 1 Alters Muscle and Bone Structure and Function in Transgenic Mice", <u>Endocrinology</u> , 143(9):3681-3690 (2002)
		Folkman, J., "Role of Angiogenesis In Tumor Growth and Metastasis", <u>Seminars in Oncology</u> , 29(6):Suppl.16:15-18 (2002)
		Freund, Y.R. and Blair, P.B., "Depression of Natural Killer Activity and Mitogen Responsiveness in Mice Treated with Pristane", <u>J. Immunol.</u> , 129:2826-2830 (1982)
		Fujiwara et al., "Assessment of Stanniocalcin-1 mRNA as a molecular marker for micrometastases of various human cancers", <u>Int. J. Oncol.</u> , 16:799-804 (2000)
		Gerritsen et al., "In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set", <u>Physiol. Genomics</u> , 10:13-20 (2002)
		Hayashi et al., "Potential Role of Hepatocyte Growth Factor, a Novel Angiogenic Growth Factor, in Peripheral Arterial Disease", <u>Circulation</u> , 100[Suppl.II]:II-301-II-308 (1999)
		Hongo et al., "Development and Characterization of Murine Monoclonal Antibodies to the Latency-Associated Peptide of Transforming Growth Factor β_1 ", <u>Hybridoma</u> , 14(3):253-260 (1995)
		Ito et al., "Angiogenesis but not collateral growth is associated with ischemia after femoral artery occlusion", <u>Am. J. Physiol.</u> , 273(3 Pt 2):H1255-H1265 (1997)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	



INFORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number:

11669.213USU1

Application Number:

09/703,350

Applicant: MEHRABAN ET AL.

Filing Date: 10/31/2000

Group Art Unit: 1642


	Jennische et al., "Expression of hepatocyte growth factor in growing and regenerating rat skeletal muscle", <u>Am J Physiol.</u> , 265(1 Pt 1):C122-C128 (1993)
	Kahn et al., "Gene Expression Profiling in an in Vitro Model of Angiogenesis", <u>American Journal of Pathology</u> , 156(6):1887-1900 (2000)
	Kohler and Milstein, "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity", <u>Nature</u> , 256:495-497 (1975)
	Koide et al., "Preparation of a Monoclonal Antibody Specific for Human Stanniocalcin", <u>Biol. Pharm. Bull.</u> , 21(12):1352-1355 (1998)
	Maulik et al., "Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition", <u>Cytokine & Growth Factor Reviews</u> , 13:41-59 (2002)
	McCudden et al., "Characterization of Mammalian Stanniocalcin Receptors", <u>Journal of Biological Chemistry</u> , 277:45249-45258 (2002)
	Miyazawa et al., "Molecular Cloning and Sequence Analysis of cDNA for Human Hepatocyte Growth Factor", <u>Biochem. & Biophys. Res. Comm.</u> , 163(2):967-973 (1989)
	Morishita et al., "Hepatocyte Growth Factor as Cardiovascular Hormone: Role of HGF in the Pathogenesis of Cardiovascular Disease", <u>Endocrine Journal</u> , 49(3):273-284 (2002)
	Nakamura et al., "Molecular Cloning and Expression of Human Hepatocyte Growth Factor", <u>Nature</u> , 342:440-443 (1989)
	Okajima et al., "Primary Structure of Rat Hepatocyte Growth Factor and Induction of Its mRNA During Liver Regeneration Following Hepatic Injury", <u>European Journal of Biochemistry</u> , 193:375-381 (1990)
	Paciga et al., "Ovarian Stanniocalcin Is Structurally Unique in Mammals and Its Production and Release Are Regulated through the Luteinizing Hormone Receptor", <u>Endocrinology</u> , 143(10):3925-3934 (2002)
	Schmidt et al., "Levels of Vascular Endothelial Growth Factor, Hepatocyte Growth Factor/Scatter Factor and Basic Fibroblast Growth Factor in Human Gliomas and Their Relation to Angiogenesis", <u>Int. J. Cancer</u> , 84:10-18 (1999)
	Scholz et al., "Ultrastructure and molecular histology of rabbit hind-limb collateral artery growth (arteriogenesis)", <u>Virchows Arch</u> , 436:257-270 (2000)
	Seki et al., "Isolation and Expression of cDNA for Different Forms of Hepatocyte Growth Factor from Human Leukocyte", <u>Biochem. and Biophys. Res. Commun.</u> , 172(1):321-327 (1990)
	Tashiro et al., "Deduced Primary Structure of Rat Hepatocyte Growth Factor and Expression of the mRNA in Rat Tissues", <u>Proc. Natl. Acad. Sci. USA</u> , 87:3200-3204 (1990)
	To et al., "The roles of hepatocyte growth factor/scatter factor and Met receptor in human cancers (Review)", <u>Oncology Reports</u> , 4:1013-1024 (1998)
	Varghese et al., "Overexpression of Human Stanniocalcin Affects Growth and Reproduction in Transgenic Mice", <u>Endocrinology</u> , 143(3):868-876 (2002)
	Wagner et al., "Human Stanniocalcin Inhibits Renal Phosphate Excretion in the Rat", <u>Journal of Bone and Mineral Research</u> , 12(2):165-171 (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.213USU1	Application Number: 09/703,350
	Applicant: MEHRABAN ET AL.	
	Filing Date: 10/31/2000	Group Art Unit: 1642



		Wagner et al., "Molecular cloning and cDNA sequence analysis of coho salmon stanniocalcin", <u>Molecular and Cellular Endocrinology</u> , 90(1):7-15 (1992)
		Wagner et al., "Purification, Characterization, and Bioassay of Teleocalcin, a Glycoprotein from Salmon Corpuscles of Stannius", <u>General and Comparative Endocrinology</u> , 63:481-491 (1986)
		Xin et al., "Hepatocyte Growth Factor Enhances Vascular Endothelial Growth Factor-Induced Angiogenesis in Vitro and in Vivo", <u>Am. J. Pathol.</u> , 158(3):1111-1120 (2001)
		Zlot et al., "Stanniocalcin I Is an Autocrine Modulator of Endothelial Angiogenic Responses to Hepatocyte Growth Factor*", <u>The Journal of Biological Chemistry</u> , 278(48):47654-47659 (2003)
		Copy of International Search Report dated January 21, 2005



EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	